. Plasma ANP is markedly increased in diseases characterized by an expanded fluid volume, including cardiac and renal insufficiency [2] [3] [4] . Circulating ANP increases with the progression of cardiac insufficiency and with the deterioration of hemodynamics; mortality and ANP are positively correlated in severe heart failure [5] [6] [7] .
ANP commonly is measured by RIA, but these methods present several analytical problems [8, 9] , mainly with detection limits and accuracy. An ideal assay of ANP should detect only the biologically active peptide (ahANP._(2(,) and not its precursors (pro-ANP1_16, yANP) or metabolites (e.g., ANP124_
126, ANP107_126, ANP, 12-126' and ANP,9_1051106126, generally called "cleaved" ANP) or other family-related peptides (brain natriuretic peptide, C natriuretic peptide, and urodilatin) [2] [3] [4] .
More recently, IRMA methods for measuring plasma ANP have been reported [10, 11] and currently show better sensitivity, precision, and accuracy than the previously reported RIAs. In addition, because IRMAs do not generally require preliminary extraction or purification of the plasma sample, they may be more suitable than RIAs for the routine assay of plasma ANP concentrations.
Given the lack of data concerning the usefulness of IRMA methods in follow-up of patients with cardiac diseases, we evaluated the analytical characteristics and the clinical utility of a commercially available IRMA kit for assaying plasma ANP.
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Materials and Methods
EXPERIMENTAL SUBJECTS
We studied 59 subjects (ages 20-75 years, 25 men and 34 women), who denied serious disease (past or present) and the use of any drug for at least 3 weeks before the study. excluded from the study. Informed consent was obtained from all subjects studied, and the protocol study was approved by the local ethics commission.
PLASMA SAMPLES
Unknown plasma samples. Unless otherwise stated, blood was collected from a brachial vein after at least 20 mm of rest in recumbent position between 0800 and 1000 after an overnight fast. Moreover, in some cardiac patients, to evaluate the influence of body posture on ANP concentrations, we studied blood samples that had been collected immediately, and (or) after 20 mm of rest in recumbent position, and (or) after 20 mm of upright position. Finally, in some cardiac patients, who underwent complete hemodynamic studies because of their cardiac disease, blood samples were also taken from different sites (e.g., brachial vein, aorta, pulmonary artery, and inferior vena cava). Immediately after collection, the blood samples were put into ice-chilled disposable polypropylene tubes containing aprotinin (500 000 kIU/L of plasma) and EDTA(l g/L of plasma). Plasma samples were separated without delay by centrifugation for 10 mm at 4 #{176}C, and then frozen and stored at -20 #{176}C in different I -mL aliquots in polypropylene assay tubes until assay (generally within 2 weeks).
Plasma pools. Four plasma pools were prepared for use in quality-control studies. Two quality-control pools were prepared from plasma samples collected (as described above) from healthy subjects; two other pools of plasma were collected from patients with heart failure. Aliquots (1 mL) of -30 different plasma samples from healthy subjects or cardiac patients were collected in two separate beakers. After a 30-mm agitation at room temperature with magnetic stirring, I -mL aliquots from each pool were put into separate polypropylene tubes and stored at -20 #{176}C until assay.
ANP-free pooled plasma was prepared by treating pooled plasma from healthy subjects with grossly ground charcoal (250 g/L of plasma), as previously described [12] . ANP by Calbiochem-Novabiochem, Laufelfingen, Switzerland) was iodinated with Na125I (Sorin, Saluggia Vercelli, Italy), and the mixture was then purified by both ion-exchange chromatography and HPLC [13] . Degradation of '251-labeled ANP was then determined by a chromatographic procedure, as previously described [13] [14] [15] [16] [17] Again aspirate the contents of the tubes and wash twice with 1 mL of the washing solution. Although the manufacturer does not specify this point, it is important to perform the aspiration/washing steps at low temperature, i.e., keep the tubes in an ice bath to not perturb the equilibrium of antigen/ antibody complex reached during this step. Finally, count for 1 mm with a gamma scintillation counter the radioactivity remaining bound to the beads.
As indicated by the manufacturer, the IRMA shows cross- These data indicate that this IRMA is specific for the biologically active part of the peptide [1] [2] [3] [4] .
STATISTICAL ANALYSIS
All sample values and the other data for quality control (including the sensitivity and the imprecision profile) were calculated for each assay by a previously described computer program [18] : The interpolation of the dose-response curves was computed with a four-parameter logistic function [18] . In particular, the 
Results
STABILITY OF ANP IN BLOOD
AND PLASMA
A known amount of labeled ANP was added to six blood samples containing plasma protease inhibitors (i.e., EDTA and aprotinm) and collected from the healthy control subjects or from cardiac patients. These specimens were then incubated for 5 mm at room temperature.
After separation by centrifugation, the percentage of ANP degradation in plasma was tested by HPLC (mean ± SD degradation, 9.7% ± 1.7%). Moreover, another aliquot of two of these blood specimens was incubated for 2 h at room temperature before centrifugation; the mean degradation found in plasma after separation by centrifugation averaged 33.0%. Finally, another aliquot of two of these blood specimens was hemolyzed by freezing at -80 #{176}C for 10 mm and then incubated at room temperature for 5 mm before centrifugation; the percentage of degradation in these two specimens averaged 56.5%.
A known amount of '25I-labeled AN? was added to four 2-mL specimens from the same plasma pool, with or without plasma protease inhibitors (EDTA and aprotinin); two of these samples were incubated for 2 mm at 37 #{176}C and the others for 30 mm at 37 #{176}C. After incubation, the percentage of degradation was tested in duplicate by HPLC assay. The degradation of tracer in the specimens incubated for 2 mm averaged 4.2% for the specimen not containing protease inhibitors, whereas results for the specimen containing inhibitors were superimposable on that of the tracer added (i.e., within 0.8% by the IRM k in the four plasma control pools, prepared with plasma samples collected from the control subjects or the patients with heart failure, were shown to be stable for 12 months (see Between-assay precision).
EVALUATION OF IRMA ANALYTICAL PERFORMANCE
Calibration curve, workingrange, andsensitivity. Fig. 1 Between-assay precision. The between-assay precision was repeat.. edly tested throughout 1 year by assaying four plasma pools with different ANP concentrations.
The observed values were 11.4%
(mean ± SD = 22.6 ± 2.6 ng/L, n = 12) and 10.7% (mean ± SD = 25.6 ± 2.7 ng/L, n = 8) for the two pools collected from the control subjects, and 8.0% (178.6 ± 14.3 ng/L, n 12) and 6.7% (162.2 ± 10.8 ng/L, n = 8) for the two pools collected from patients with cardiac insufficiency.
Dilution test.
As assayed with the IRMA, various volumes (from 50 to 300 ILL) of plasma samples of two patients with heart failure, containing relatively high concentrations of ANP, showed a close linear regression between the plasma volume assayed and the ANP measured (Fig. 2) . Although the manufacturer of IRMA kit suggests assaying 100 ILL of a patient's plasma, the results of these dilution tests indicate that one can validly increase the volume (until 300 ILL) of plasma assayed and thus improve the precision of the determination of samples with low ANP contents, as indicated in Fig. I B.
Recovery test. An ampoule containing 100 g of synthetic ANP (Calbiochem-Novabiochem) was appropriately diluted with the IRMA kit buffer and then repeatedly (n = 8) assayed; the mean analytical recovery was 98.8% ± 5.3%. Furthermore, the mean recovery of known amounts (5-2 000 ng/L) of synthetic peptide added to seven ANP-free plasma samples (containing EDTA and aprotinin) was 99.5% ± 18.8%. (at room temperature, 18-22 #{176}C for 3 h), vs the mean (± SE, n = 8) calibration curve obtained by performing the first incubation at 4-8 #{176}C for 12 h; (B) mean (± SE) imprecision profiles (CV, %) of the IRMA kit, obtained by performing the first incubation by the manufacturer's instructions, vs that found by using a first incubation at 4-8 #{176}C for 12 h. The imprecision profile was calculated from results for all of the samples measured in one assay (i.e.. calibrators, quality-controlsamples, and unknown samples from healthy subjects or patients). The working range was arbitrarily defined as the range of ANP concentration measured with an imprecision of <15%.
CLINICAL RESULTS
Body
200
Volume of plasma assayed, tL Left ventflcularejection fractIon, % ng/L), whereas cardiac patients with more severe symptoms of heart failure generally show greatly increased hormonal values (NYHA III and W, 257.4 ± 196.6 ngfL) (Fig. 3) .
Moreover, we observed a significant negative linear regression (P <0.0001) between the logarithmic transformation of plasma ANP concentrations and the ventricular ejection fraction values in 62 cardiac patients (Fig. 4) , suggesting that AN? concentrations may also be related to the degree of myocardial dysfunction. methods [10, Il] . Furthermore, our results indicate that assay precision and sensitivity can be further increased by using a longer time (12 h overnight) and a lower temperature (4-8 #{176}C) for the first incubation than suggested by the manufacturer. We could also increase the minimum amount of ANP measured per tube by assaying a greater volume of plasma than the 100 ILL suggested by the manufacturer.
ANP concentrations in aorta
Using the IRMA kit, we were able to assay the circulating concentrations of ANP in all of the control subjects with acceptable precision. Available RIA methods frequently do not permit precise measurement of ANP concentrations in plasma samples from healthy controls [8, 9] . Indeed, as we previously reported [8, 9] , some commercially available RIA kits, evaluated in our laboratory by the same procedures reported here, had detection limits between 10 and 20 ng/L, whereas that of the IRMA kit was -2 ngfL (i.e., 5-10 times better than R.IA). Moreover, the between-assay imprecision (CV, %) of RIA methods was generally >20% [8, 9] , vs a between-assay imprecision of the IRMA kit of 6.7-11.4%
for four different qualitycontrol plasma pools. Finally, the RIAs generally required a preliminary extraction of plasma samples and more sample volume (-1-3 mL) for the assay [8, 9] than did the IRMA kit (50-300 ILL) (Fig. 2) . Consequently, our data clearly demonstrate that the IRMA is preferable to RIAs for the routine assay of plasma ANP.
Our study shows that a well-standardized protocol should be used in the routine determination of plasma ANP by immunoassay, because sample collection and storage may greatly affect the plasma ANP concentrations.
In particular, blood samples should be centrifuged immediately and the plasma should be separated and stored at -20 #{176}C as soon as possible, because of findings that some blood cells (probably platelets, which share ANP receptors) [19, 20] can degrade ANP even in presence of plasma protease inhibitors.
Plasma samples with evident hemolysis should be discarded and not assayed. The clinical results obtained with the IRMA kit agreed well with those by previously described RIA and IRMA methods [8] [9] [10] [11] [21] [22] [23] [24] [25] [26] [27] . The reference range for healthy subjects is similar to that generally reported by the most accurate methods, e.g., other IRIVIAs [10, Ii] or RIAs that use a preliminary extraction and purification of plasma samples with chromatographic procedures [2-4, 9, 21] . Our findings also confirm that the circulating concentrations of ANP were increased in patients with cardiac failure [5] [6] [7] . Indeed, plasma ANP increaseswith the progression of clinical severity of the disease, so some patients with only mild symptoms of diseases (NYI-IA I or II) and (or) initial myocardial involvement (ejection fraction >50%) could have ANP concentrations within the reference range. Cardiac patients with more severe symptoms of heart failure (NYHA III-IV) and myocardial dysfunction (ejection fraction <25%) currently show greatly increased values-as much as 30 times the mean value for healthy subjects (Figs. 3 and 4) .
The main analytical characteristics of the IRMA (high sensitivity and precision, low assay volume) make it possible to accurately measure ANP concentrations during dynamic tests or pathophysiological studies, in which only a few milliliters of blood can be withdrawn, e.g., when several blood samples must be collected in a short period of time, or several analytes must be assayed in each sample. Indeed, we used the IRMA kit to simultaneously and repeatedly measure ANP concentrations in two (or more) different sites of circulation in the same patient. Our results are in complete agreement with several reports of data [28] [29] [30] [31] [32] [33] showing nearly superimposable values of ANP plasma concentrations measured either in the pulmonary artery or in the aorta, whereas these ANP concentrations differed greatly from those in the inferior vena cava, confirming the important role of peripheral tissues in ANP clearance.
In conclusion, the IRMA kit we evaluated for ANP determination showed a good sensitivity, precision, and practicability and gave results that were superimposable on those obtained with previously described IRMAs [JO, 11] but much better than those obtained by RIAs requiring a preliminary chromatographic extraction and purification of plasma samples [8, 9] . Moreover, the clinical results observed with this method were well in agreement with those found with other accurate methods (IRMAs or RIAs with preliminary chromatographic purification). Consequently, we prefer the IRMA over RIA for measuring plasma ANP, both for experimental studies and for routine assays in patients with heart failure.
